William J. Gradishar, MD
Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine
Denise A. Yardley, MD
Program Director, Breast Cancer Research
Sarah Cannon Research Institute
Joyce A. O’Shaughnessy, MD
Co-Chair, Breast Cancer Research
Baylor - Charles A. Sammons Cancer Center
Texas Oncology PA
Terry P. Mamounas, MD, MPH
Associate Professor of Surgery
Northeastern Ohio Universities College of Medicine
Medical Director, Aultman Cancer Center
Physician CME: 2.0
CREDIT FOR THIS PROGRAM IS AVAILABLE TO PHYSICIANS, ONLY.
This online capture of a satellite symposium was originally presented on December 14, 2007, in conjunction with the 30th Annual San Antonio Breast Cancer Symposium (SABCS). If you received credit from the live symposium, you are not eligible to apply for credit through this online version.
Breast cancer is the most common cancer among women in the United States and is second only to lung cancer as the leading cause of cancer deaths. The past 10 years have witnessed important changes in virtually every aspect of diagnosis and treatment for breast cancer. The widespread use of adjuvant systemic therapy in early stage breast cancer has led to a reduction in breast cancer mortality. Likewise, discoveries in molecular signaling pathways and the translational application of these findings have resulted in the direct development of novel hormonal and biologic therapies. These targets and agents – either alone or in combination with chemotherapy – have translated into better outcomes, both in the early stage as well as in the advanced disease setting.
. Target Audience
This educational activity is designed to meet the needs of medical oncologists and other physicians involved in the treatment of patients with breast cancer.
Upon completion of this educational activity, the participant should be able to:
Review results from recent clinical studies evaluating combination regimens of antimetabolites and taxanes for metastatic breast cancer.
Evaluate the criteria in selecting patients for sequential or combination chemotherapy.
Discuss the clinical implications of combining nucleoside analogues with targeted biologic agents when treating advanced breast cancer.
Explore the evolving role of nucleoside analogues for adjuvant or neoadjuvant chemotherapy in breast cancer patients.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
This educational activity may contain discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Mamounas discloses speakers’ bureau service for Aventis, Eli Lilly, Genentech, Genomic Health, and Pfizer. He also participates in advisory committees for Abraxis, Aventis, Bristol-Myers Squibb, Eli Lilly, Genomic Health, GlaxoSmithKline, Onyx Bayer, Novartis, Roche, and Pfizer.
Dr. O’Shaughnessy discloses advisory committee participation for Abraxis, Biogen, Eisai, Eli Lilly, Genentech, Genzyme, Novartis, Pfizer, and Sanofi-Aventis. She also provides speakers’ bureau service for Abraxis, AstraZeneca, Eli Lilly, and Sanofi-Aventis.
Drs. Gradishar and Yardley claim no actual or potential conflict of interest to this program.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH, Inc. and Medical Communications Media, Incorporated. AKH, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH, Inc. designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. There is no fee to participate and receive credit.
Commercial Support Statements
This activity is supported by an educational grant from Eli Lilly and Company.
Please turn off all pop-up blockers and click on the "Start Program" icon at the bottom of the page. If you have not previously registered with this website, you will be taken to the login/registration page where you will be able to register as a new CMEcorner.com member. If you have previously registered, you will be asked to verify or correct existing registration information. When ready, click on the "Start Program" icon.
The next screen will be a brief pre-program survey. Please complete the survey and click on the "Done" button on the bottom of the page. Please wait while you are connected to the video server. This program, question-and-answer session, post-test, and evaluation will take approximately 120 minutes to complete.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME certificate. One retake is permitted.
©2008 Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and in the related educational event are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the SABCS, or Eli Lilly and Company. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.